Table 1.
Baseline demographic, clinical and procedural characteristics of the study patients
| SOC (n = 48) | SOC + EM (n = 25) | IC (n = 50) | |
|---|---|---|---|
| Demographics | |||
| Race (Caucasian) | 43 (89.6) | 22 (88.0) | 49 (98.0) |
| Age, years | 64.0 ± 10.6 | 66.7 ± 8.3 | 65.5 ± 11.3 |
| Gender (male) | 42 (87.5) | 19 (76.0) | 43 (86.0) |
| BMI, kg m –2 | 28.2 ± 3.7 | 28.3 ± 3.4 | 26.8 ± 5.2 |
| Cardiovascular risks factors | |||
| Diabetes | 14 (29.2) | 7 (28.0) | 8 (16.0) |
| Hypertension | 40 (83.3) | 21 (84.0) | 38 (76.0) |
| Dyslipidaemia | 45 (93.8) | 22 (88.0) | 46 (92.0) |
| Smoker (current or former) | 35 (72.9) | 18 (72.0) | 31 (62.0) |
| Indication for revascularization | |||
| Stable angina | 21 (43.8) | 9 (36.0) | 15 (30.0) |
| Unstable angina | 4 (9.1) | 6 (25.0) | 8 (16.7) |
| Positive functional test | 13 (27.1) | 4 (16.0) | 9 (18.0) |
| Elective stent post‐ACS | 14 (29.2) | 8 (32.0) | 22 (44.0) |
| Number of stents | 1.5 ± 0.5 | 1.3 ± 0.7 | 1.4 ± 0.6 |
| Number of drug‐eluted stents | 1.5 ± 0.5 | 1.3 ± 0.8 | 1.4 ± 0.6 |
| Number of bare metal stents | 0.7 ± 0.6 | 1.3 ± 0.6 | 1.0 ± 0 |
| Prior cardiac history | |||
| ACS | 26 (54.2) | 11 (44.0) | 28 (56.0) |
| Coronary artery bypass graft | 7 (14.6) | 3 (12.0) | 8 (16.0) |
| PCI without stent | 11 (22.9) | 4 (16.0) | 7 (14.0) |
| PCI with stent | 27 (56.3) | 13 (52.0) | 25 (50.0) |
| Pharmacotherapy | |||
| Aspirin | 48 (100.0) | 24 (96.0) | 50 (100.0) |
| Beta‐blocker | 35 (72.9) | 16 (64.0) | 38 (76.0) |
| RAAS ‐inhibitor | 41 (85.4) | 21 (84.0) | 42 (84.0) |
| Calcium channel blocker | 9 (18.8) | 5 (20.0) | 2 (4.0) |
| Diuretic | 15 (31.3) | 5 (20.0) | 9 (18.0) |
| Statin | 47 (97.9) | 23 (92.0) | 48 (96.0) |
| Pantoprazole | 14 (29.2) | 5 (20.0) | 13 (26.0) |
| Laboratory results | |||
| Serum creatinine, μmol l –1 | 84 ± 20 | 85 ± 19 | 92 ± 22 |
| eGFR ckd‐epi, ml min –1 1. 73m – 2 | 83.6 ± 16.5 | 78.5 ± 14.8 | 75.7 ± 18.1 |
| Total cholesterol, mmol l –1 | 4.3 ± 1.0 | 4.3 ± 0.7 | 4.1 ± 0.8 |
| LDL‐cholesterol, mmol l –1 | 2.3 ± 0.8 | 2.4 ± 0.6 | 2.2 ± 0.8 |
| HDL‐cholesterol, mmol l –1 | 1.3 ± 0.4 | 1.3 ± 0.2 | 1.3 ± 0.4 |
| Fasting glucose, mmol l –1 | 6.6 ± 1.9 | 6.4 ± 1.7 | 6.1 ± 1.5 |
| Haemoglobin, g l –1 | 144 ± 15 | 140 ± 11 | 145 ± 12 |
| Platelets, cells μl –1 | 219 ± 64 | 229 ± 64 | 232 ± 65 |
| Genotyping | |||
| CYP2C19*2 allele noncarriers | 38 (79.2) | 17 (68.0) | 38 (76.0) |
| CYP2C19*2 allele carriers | 10 (20.8) | 8 (32.0) | 12 (24.0) |
Values are expressed as means ± standard deviation or n, with percentages in parenthesis. There were no significant differences (at P < 0.05) between groups in any of the summarized characteristics, with the exception of the use of calcium channel blockers (P = 0.048). ACS, acute coronary syndrome; BMI, body mass index; CYP, cytochrome P450; eGFR ckd‐epi, estimated glomerular function rate – chronic kidney disease epidemiology collaboration; HDL, high‐density lipoprotein; IC, integrated care; LDL, low‐density lipoprotein; PCI, percutaneous coronary intervention; RAAS, renin–angiotensin–aldosterone system; SOC, standard of care; SOC + EM, standard of care + adherence electronic monitoring